Abstract
| Lingua originale | English |
|---|---|
| pagine (da-a) | 1869-1873 |
| Numero di pagine | 5 |
| Rivista | Expert Opinion on Pharmacotherapy |
| Volume | 14 |
| Stato di pubblicazione | Published - 2013 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Pharmacology (medical)
Cita questo
Emerging approaches for the treatment of hypertriglyceridemia. / Montalto, Giuseppe; Rizzo, Manfredi; Nikolic, Dragana; Perez-Martinez, Pablo; Lopez-Miranda, Jose; Rizzo, Manfredi.
In: Expert Opinion on Pharmacotherapy, Vol. 14, 2013, pag. 1869-1873.Risultato della ricerca: Article
}
TY - JOUR
T1 - Emerging approaches for the treatment of hypertriglyceridemia.
AU - Montalto, Giuseppe
AU - Rizzo, Manfredi
AU - Nikolic, Dragana
AU - Perez-Martinez, Pablo
AU - Lopez-Miranda, Jose
AU - Rizzo, Manfredi
PY - 2013
Y1 - 2013
N2 - Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjects with hypertriglyceridemia. However, a consensus on the optimal clinical use of these pharmacological agents is not fully established yet, and additional large clinical studies are needed. It seems that there is a favorable association between fish consumption and mortality from CVD, but it remains to be confirmed by future trials. Finally, there are a number of novel therapies, such as those targeting microsomal transport protein and its inhibitors, which represent new promising option for treating subjects with hypertriglyceridemia.
AB - Hypertriglyceridemia is frequent in diabetic and obese subjects, who are at increased risk for cardiovascular diseases (CVD). Increased triglycerides (TG) are a hallmark of atherogenic dyslipidemia, representing a marker of atherogenic small dense low-density lipoproteins (sdlDL). Importantly, non-fasting/postprandial TG measurements tend to be emphasized in clinical practice for the prediction of CVD, and TG-lowering agents (primarily fibrates) have a beneficial effect on atherogenic dyslipidemia, reducing TG-rich particles and ultimately lowering the production of sdlDL. The combination of omega-3 fatty acids and statins is also recommended, and widely used in clinical practice for subjects with hypertriglyceridemia. However, a consensus on the optimal clinical use of these pharmacological agents is not fully established yet, and additional large clinical studies are needed. It seems that there is a favorable association between fish consumption and mortality from CVD, but it remains to be confirmed by future trials. Finally, there are a number of novel therapies, such as those targeting microsomal transport protein and its inhibitors, which represent new promising option for treating subjects with hypertriglyceridemia.
UR - http://hdl.handle.net/10447/104538
UR - http://www.ncbi.nlm.nih.gov/pubmed/24011268
M3 - Article
VL - 14
SP - 1869
EP - 1873
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
ER -